Neuregulin-1β for the treatment of systolic heart failure.
about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesPhenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injuryIntravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction.Platelet endothelial cell adhesion molecule-1 mediates endothelial-cardiomyocyte communication and regulates cardiac function.The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferationCardiac side effects of anticancer treatments: new mechanistic insightsAn engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in miceNovel biomarkers in chronic heart failure.Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function.Novel drug targets in clinical development for heart failure.Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).New Targets in the Drug Treatment of Heart Failure.The Src homology and collagen A (ShcA) adaptor protein is required for the spatial organization of the costamere/Z-disk network during heart development.Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa).ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes.Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms?.
P2860
Q26746907-1A54CA50-31E2-4A88-8E8E-AEA366A408C3Q30384457-D04541C1-C55E-49C0-8838-13E401E42EB9Q34312113-3CCCBB72-C955-4B54-B23E-1CB76F5E42C3Q34598168-B622ABF3-F066-46F3-AA47-0192DD8A934CQ35088053-A0F24656-9D6B-4A53-B4AA-3F4F5C34E855Q36042588-241585B0-1BF8-4ED8-8094-76F67FBEC798Q36957758-DAB5D85E-5DE4-4B4C-8D77-2AE78BC3773AQ37121891-F9A0A94D-AD2D-44B7-8B3D-CB6814B1953AQ37288691-0AEA9B7C-66D2-4F20-9369-5B02378BBDD3Q37686822-5D683478-14DA-4B0F-9B19-D03320F6A392Q37997237-C8F65912-4206-4FC1-A1F1-B1F8F7B47D48Q38025012-A176995C-7937-4AB3-AFDF-459E191142ACQ38202895-4BB154C3-66ED-4928-B210-1DA4448AF5DFQ38546917-65611DC1-538C-4F76-BC46-D482214DFE5CQ38667210-A4B1D856-7938-4F00-8083-C328752A5EBDQ41863155-1F0470DF-19A8-4293-A464-30C0220783B3Q47719721-3C8104A5-9523-4BA8-BCAA-47CCD8FA0335Q50992137-53599850-3A1E-4682-9568-52CE85AEEDBBQ53193638-2A9E5553-2107-4B64-BBC8-8C851AF8C808Q54489633-9E47757E-7692-4747-8CB5-A9F0645C9787
P2860
Neuregulin-1β for the treatment of systolic heart failure.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Neuregulin-1β for the treatment of systolic heart failure.
@ast
Neuregulin-1β for the treatment of systolic heart failure.
@en
type
label
Neuregulin-1β for the treatment of systolic heart failure.
@ast
Neuregulin-1β for the treatment of systolic heart failure.
@en
prefLabel
Neuregulin-1β for the treatment of systolic heart failure.
@ast
Neuregulin-1β for the treatment of systolic heart failure.
@en
P2860
P1476
Neuregulin-1β for the treatment of systolic heart failure.
@en
P2093
Anthony Caggiano
Douglas B Sawyer
P2860
P304
P356
10.1016/J.YJMCC.2011.06.016
P577
2011-06-28T00:00:00Z